Want to see RLAY full AI Analyst Report?
RLAY Stock Chart & Stats
$16.76
>-$0.01(-0.22%)
At close: 4:00 PM EST
$16.76
>-$0.01(-0.22%)
Day’s Range― - ―
52-Week Range$3.03 - $20.79
Previous CloseN/A
Volume391.09K
Average Volume (3M)4.46M
Market Cap
$4.36B
Enterprise Value$2.55B
Total Cash (Recent Filing)$642.07M
Total Debt (Recent Filing)$31.57M
Price to Earnings (P/E)―
Beta2.07
Next Earnings
Aug 06, 2026EPS Estimate
-0.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.57
Shares Outstanding217,940,340
10 Day Avg. Volume3,672,846
30 Day Avg. Volume4,459,164
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)2.56
Price to Sales (P/S)94.54
P/FCF Ratio-6.15
Enterprise Value/Market Cap0.58
Enterprise Value/Revenue238.85
Enterprise Value/Gross Profit-21.29
Enterprise Value/Ebitda-9.33
Forecast
1Y Price Target
$24.00Price Target Upside43.20% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-1.55
Revenue Forecast (FY)$12.55M
Bulls Say, Bears Say
Bulls Say
Proprietary Structure-based Discovery PlatformRelay’s computational, motion-focused discovery engine is a durable competitive asset that can increase hit quality and speed lead optimization. Over months this platform supports repeatable pipeline generation, attracts partnerships, and can lower long-term R&D unit costs versus pure empirical screening approaches.
Promising Zovegalisib Clinical DataRobust early efficacy and tolerability in PIK3CA-driven vascular anomalies materially de-risks a non-oncology rare-disease pathway. Durable value stems from potential label expansion, pediatric cohorts and a differentiated chronic-dosing profile that could create a sustainable new revenue stream beyond oncology if later trials confirm results.
Access To Capital And Low LeverageDemonstrated market access and a recent sizable equity raise, combined with low reported debt-to-equity, provide durable funding flexibility for long-cycle clinical programs. This reduces near-term liquidity risk and allows Relay to advance multiple trials and sponsor a Phase 3 without immediate cash shortfalls.
Bears Say
High Cash BurnSustained negative operating and free cash flow indicates ongoing funding needs to support R&D and trials. Over a multi-month horizon this reliance increases execution risk if capital markets tighten, forces prioritization of programs and can lead to repeated dilutive financings that affect shareholder value and strategic optionality.
Large Ongoing Losses And Negative ReturnsMaterial operating losses and negative ROE reflect that the business is not yet generating returns on invested capital. This structural unprofitability limits reinvestment from internal cash flow, raises the bar for eventual commercialization to offset accumulated losses, and increases investor dependence on successful clinical readouts.
Dilution Risk From Increased Authorized SharesA formal increase in authorized shares is a structural governance change that enables future dilution. Over months this lowers the deterrent to additional equity raises, can depress per-share economics, and signals continued external funding reliance—heightening long-term dilution risk for current shareholders.
Relay Therapeutics News
RLAY FAQ
What was Relay Therapeutics Inc’s price range in the past 12 months?
Relay Therapeutics Inc lowest stock price was $3.02 and its highest was $20.79 in the past 12 months.
What is Relay Therapeutics Inc’s market cap?
Relay Therapeutics Inc’s market cap is $4.36B.
When is Relay Therapeutics Inc’s upcoming earnings report date?
Relay Therapeutics Inc’s upcoming earnings report date is Aug 06, 2026 which is in 24 days.
How were Relay Therapeutics Inc’s earnings last quarter?
Relay Therapeutics Inc released its earnings results on May 05, 2026. The company reported -$0.41 earnings per share for the quarter, missing the consensus estimate of -$0.363 by -$0.047.
Is Relay Therapeutics Inc overvalued?
According to Wall Street analysts Relay Therapeutics Inc’s price is currently Undervalued.
Does Relay Therapeutics Inc pay dividends?
Relay Therapeutics Inc does not currently pay dividends.
What is Relay Therapeutics Inc’s EPS estimate?
Relay Therapeutics Inc’s EPS estimate is -0.39.
How many shares outstanding does Relay Therapeutics Inc have?
Relay Therapeutics Inc has 217,940,340 shares outstanding.
What happened to Relay Therapeutics Inc’s price movement after its last earnings report?
Relay Therapeutics Inc reported an EPS of -$0.41 in its last earnings report, missing expectations of -$0.363. Following the earnings report the stock price went down -0.615%.
Which hedge fund is a major shareholder of Relay Therapeutics Inc?
Currently, no hedge funds are holding shares in RLAY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Relay Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$24.00 (43.20% Upside)
$24.00 (43.20% Upside)
Blogger Sentiment
Bullish
RLAY Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 7.8M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $47.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 8.4%
Last 30 Days ▲ 16.6%
Last 30 Days ▲ 16.6%
News Sentiment
Bullish
Bullish news 75%
Bearish news 25%
Bearish news 25%
Technicals
SMA
Positive
20 days / 200 days
Momentum
436.32%
12-Months-Change
Fundamentals
Return on Equity
-43.94%
Trailing 12-Months
Asset Growth
-12.48%
Trailing 12-Months
Company Description
Relay Therapeutics Inc
Relay Therapeutics, Inc. is a precision medicine company currently engaged in clinical trials. Its central mission involves revolutionizing the drug discovery process, with a particular focus on enhancing the creation of small molecule therapies for specific types of cancer and genetic conditions. The company's pipeline features several promising drug candidates: RLY-4008, an orally administered small molecule designed to inhibit fibroblast growth factor receptor 2 (FGFR2), which is undergoing its initial human trials for patients with advanced or metastatic solid tumors exhibiting FGFR2 alterations; RLY-2608, a leading program targeting mutant phosphoinositide 3 kinase alpha (PI3Ka); and RLY-1971, another oral small molecule, an inhibitor of SHP2 (protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2), currently in Phase 1 trials for individuals with advanced solid tumors. Relay Therapeutics has established strategic partnerships, including a collaboration with D. E. Shaw Research, LLC, which utilizes computational modeling to analyze protein motion for the identification and development of therapeutic compounds. Furthermore, an agreement with Genentech, Inc. supports the development and commercialization of RLY-1971. Founded in 2015 as Allostery, Inc., the company rebranded to Relay Therapeutics, Inc. in December of that year and maintains its headquarters in Cambridge, Massachusetts.
RLAY Stock 12 Month Forecast
Average Price Target
$24.00
▲(43.20% Upside)
Technical Analysis
Ownership Overview
1.82% Insiders
11.28% Mutual Funds
0.43% Other Institutional Investors
72.36% Public Companies and
Individual Investors